Azeliragon

An inhibitor of RAGE

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1400.00

1120.00

- +
10mg

￥2312.00

1850.00

- +
50mg

￥8100.00

6480.00

- +
100mg

￥12962.00

10370.00

- +
200mg

￥21062.00

16850.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci22348
CAS: 603148-36-3
别名: 阿齐瑞格; TTP488; PF-04494700
分子式: C32H38ClN3O2
分子量: 532.12
纯度: >98%
溶解度: DMSO : 50 mg/mL (93.96 mM);Water : < 0.1 mg/mL (insoluble)
储存: Store at -20°C
库存: 现货

Background

TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).Target: RAGEin vitro: TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of TTP488 in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices.[1]in vivo: The small molecule RAGE antagonist, TTP488, is developed by Trans-Tech Pharma. The TTP488 or control peptide is administered i.p. daily at a dose of 100 mcg/d.[3] Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients.[2]

参考文献:
[1]. Burstein AH, et al. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014 Jan 15;14:12.
[2]. Saito S, et al. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci. 2014 Oct 20;6:290.
[3]. Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-4278.